Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brimonidine · 1 trial · 4 indications
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1
| Arm | Type | Description |
|---|---|---|
| Aceclidine + Brimonidine (LNZ101) dosed bilaterally | EXPERIMENTAL | LNZ101 (Aceclidine /Brimonidine) ophthalmic solution |
| Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally | EXPERIMENTAL | LNZ100 (Aceclidine) ophthalmic solution |
| Brimonidine ophthalmic solution dosed bilaterally | EXPERIMENTAL | Brimonidine ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Aceclidine+Brimonidine combination ophthalmic solution | DRUG | LNZ101 (Aceclidine/Brimonidine) ophthalmic solution |
| Aceclidine ophthalmic solution | DRUG | LNZ100 Aceclidine ophthalmic solution |
| Brimonidine | DRUG | Brimonidine ophthalmic solution |
Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study visits; 3. Be 45-75 years...
Brimonidine is an investigational small molecule being developed by LENZ Therapeutics for the treatment of presbyopia, an age-related condition that reduces the eye's ability to focus on near objects. It is administered as an eye drop and is currently in Phase 3 clinical development.
Brimonidine is a small molecule that acts on the eye to improve near vision in patients with presbyopia. Its specific molecular target has not been disclosed in the available information, but it is being evaluated for its ability to address the focusing difficulties associated with the condition.
Brimonidine is being developed by LENZ Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol LENZ. The company is conducting clinical trials to evaluate the safety and efficacy of Brimonidine for the treatment of presbyopia.
Brimonidine is in Phase 3 clinical development for presbyopia. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 3 trial has been completed, and the drug remains under investigation for this indication.
Brimonidine has been studied in one completed Phase 3 clinical trial with the identifier NCT05656027. This randomized, double-blind, controlled trial enrolled 469 participants aged 45 years and older in the United States to evaluate the safety and efficacy of Brimonidine for the treatment of presbyopia.